Literature DB >> 12050554

Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer.

H G van der Poel1, B Molenaar, V W van Beusechem, H J Haisma, R Rodriguez, D T Curiel, W R Gerritsen.   

Abstract

PURPOSE: We evaluated the delivery and oncolytic potential of targeted replication competent adenoviruses in bladder cancer lines.
MATERIALS AND METHODS: Seven established human bladder cancer tumor lines (5637, SW800, TCCsup, J82, Scaber, T24 and 253J) were studied for the expression of integrins alpha(v)beta3, alpha(v)beta5, Coxsackievirus and adenovirus receptor, epidermal growth factor receptor (EGF-R) and epithelial cell adhesion molecule antigens using flow cytometry analysis. Bispecific single chain Fv fragments were used to target replication deficient luciferase reporter adenovirus to EGF-R (425-s11) or to epithelial cell adhesion molecule (C28-s11) antigens. Moreover, a fiber modified adenovirus targeting alpha(v)-integrins was studied. Replication competent serotype-5 adenoviruses attenuated to replicate specifically in retinoblastoma pRb (Ad5-d24) or p53 deficient (Ad5-d55K) cells were tested in vitro for oncolytic properties.
RESULTS: Low to absent Coxsackievirus and adenovirus receptor expression was found in 5 of the 7 tumor lines (SW800, J82, T24, 5637 and Scaber). EGF-R expression was found in all cell lines, whereas elevated epithelial cell adhesion molecule expression was seen in 3 (5637, Scaber and TCCsup), alpha(v)beta3-integrin was found in 1 (Scaber) and alpha(v)beta5-integrin was found in 3 (TCCsup, 253J and T24). EGF-R targeting using 425-s11 improved transgene expression in all cell lines from 2.1 to 12.5 times over nontargeted viruses. Epithelial cell adhesion molecule and integrin targeting was inferior to EGF-R targeting with a maximal increase in transgene expression of 2 times for epithelial cell adhesion molecule in 5637cells and 1.6 times for integrin targeting in T24 cells. Comparison of the wild-type replication competent virus with conditionally replicating adenoviruses (Ad5-d55K and Ad5-d24) showed superior oncolytic activity for the latter 2 in all lines. Furthermore, improved cytotoxicity (29% to 33%) was obtained in 4 of the 7 lines after pre-incubation of Ad5-d24 with 425-s11.
CONCLUSIONS: EGF-R directed bispecific single chain antibodies enhance adenovirus mediated transgene expression and oncolysis in bladder cancer lines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050554     DOI: 10.1097/00005392-200207000-00089

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

2.  Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Authors:  T J Harvey; D Burdon; L Steele; N Ingram; G D Hall; P J Selby; R G Vile; P A Cooper; S D Shnyder; J D Chester
Journal:  Gene Ther       Date:  2010-04-22       Impact factor: 5.250

3.  Genetically targeted adenovirus vector directed to CD40-expressing cells.

Authors:  Natalya Belousova; Nikolay Korokhov; Valentina Krendelshchikova; Vera Simonenko; Galina Mikheeva; Pierre L Triozzi; Wayne A Aldrich; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Primary targeting of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha against hepatocellular carcinoma.

Authors:  Jing Zhang; Yan-Fang Liu; Shou-Jing Yang; Qing Qiao; Hong Cheng; Chuan-Shan Zhang; Fu-Cheng Ma; Hua-Zhang Guo
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

5.  Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.

Authors:  Laura M Kasman; Sutapa Barua; Ping Lu; Kaushal Rege; Christina Voelkel-Johnson
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

6.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

7.  Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity.

Authors:  X Fu; L Tao; A Rivera; H Xu; X Zhang
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

8.  Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.

Authors:  J-L Hsieh; C-L Wu; M-D Lai; C-H Lee; C-S Tsai; A-L Shiau
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.